REQUEST A DEMO
Total
USD $0.00
Search more companies

CJ Bioscience, Inc. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: CJ Bioscience, Inc. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company principally engaged in the provision of microbial bioinformatics platform and solutions. The Company mainly provides microbial bioinformatics analysis services and microbiome-based healthcare services through bioinformatics database and cloud analytics platform. The Company also develops microbiome therapies and infection diagnosis solutions. The Company was established on November 18, 2009. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 26, 2019.

Headquarters
6F, 2477, Nambusunhwan-Ro, Seocho-Gu
Seoul; Seoul;

Contact Details: Purchase the CJ Bioscience, Inc. report to view the information.

Website: http://www.chunlab.com

Basic Information
Total Employees:
Purchase the CJ Bioscience, Inc. report to view the information.
Outstanding Shares:
Purchase the CJ Bioscience, Inc. report to view the information.
Registered Capital:
Purchase the CJ Bioscience, Inc. report to view the information.
Financial Auditors:
Purchase the CJ Bioscience, Inc. report to view the information.
Incorporation Date:
November 18, 2009
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
씨제이바이오사이언스㈜
Company Performance
Financial values in the chart are available after CJ Bioscience, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-13.67%
Total operating revenue
-14.1%
Operating profit (EBIT)
-4.79%
EBITDA
-8.13%
Net Profit (Loss) for the Period
-1.33%
Total assets
0.04%
Total equity
50.57%
Operating Profit Margin (ROS)
-136.87%
Net Profit Margin
-108.75%
Return on Equity (ROE)
5.6%
Debt to Equity Ratio
-46.85%
Quick Ratio
3.08%
Cash Ratio
3.03%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?